Forte Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Forte Biosciences, Inc. carries a market capitalization of 1.63B, placing it among publicly traded companies globally.
| Market Cap | 1.63B |
| Enterprise Value | N/A |
Share Statistics
Forte Biosciences, Inc. currently has 20.48M shares outstanding.
| Shares Outstanding | 20.48M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.37 |
| P/TBV Ratio | 2.37 |
| P/FCF Ratio | -5.85 |
| P/OCF Ratio | -5.85 |
Financial Position
Forte Biosciences, Inc. maintains a current ratio of 10.01, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.01 |
| Quick Ratio | 9.82 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -62.28 |
| Return on Assets (ROA) | -56.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 566,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Forte Biosciences, Inc.'s stock has gained approximately 456.28613% over the past 52 weeks. The 50-day moving average sits at 54.00, while the 200-day moving average is 32.96.
| Beta (5Y) | N/A |
| 52-Week Price Change | 456.28613% |
| 50-Day Moving Average | 54.00 |
| 200-Day Moving Average | 32.96 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -89.92M, while operating income came in at -90.00M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -90.00M |
| Pretax Income | -86.33M |
| Net Income | -87.94M |
| EBITDA | -89.92M |
| EBIT | -90.00M |
| Earnings Per Share (EPS) | -4.44 |
Balance Sheet
Total book value stands at 183.79M, with working capital of 182.81M providing operational flexibility.
| Cash & Cash Equivalents | 198.46M |
| Total Debt | N/A |
| Net Debt | -49.63M |
| Equity (Book Value) | 183.79M |
| Book Value Per Share | 8.97 |
| Working Capital | 182.81M |
Cash Flow
Forte Biosciences, Inc. produced -71.98M in operating cash flow over the past twelve months. After subtracting -55,000.00 in capital expenditures, free cash flow totaled -72.03M - equivalent to -3.64 per share.
| Operating Cash Flow | -71.98M |
| Capital Expenditures | -55,000.00 |
| Free Cash Flow | -72.03M |
| FCF Per Share | -3.64 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -37.53 |
| FCF Yield | -17.09 |
Stock Splits
Forte Biosciences, Inc.'s most recent stock split took place on August 28, 2024 with a 25:1 split ratio.
| Last Split Date | 8/28/2024 |
| Split Ratio | 25:1 |
Scores
Forte Biosciences, Inc. posts an Altman Z-Score of 9.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.69 |